2021
Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study.
Afghahi A, Marsh S, Winchester A, Gao D, Parris H, Axell L, Ellisen L, Hofstatter E, Kurian A, Wood M, Zakalik D, Mullin C, Caswell-Jin J, Borges V, Tung N. Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study. Journal Of Clinical Oncology 2021, 39: 10531-10531. DOI: 10.1200/jco.2021.39.15_suppl.10531.Peer-Reviewed Original ResearchCHEK2 pathogenic variantsRecurrence scoreCase-control studyMedian RSBreast cancerPathogenic variantsHigh riskRisk groupsMutation statusHER2-negative BC patientsPR-negative breast cancerMulti-site case-control studyPatient-level clinical dataRS risk groupsLymph node statusHigh recurrence scoreLow-risk groupGermline pathogenic variantsSporadic breast cancerGenetic testing resultsElectronic medical recordsAdjuvant therapyChemotherapy benefitNode statusT stage
2017
Comparison of epigenetic aging in normal breast tissue from women with and without breast cancer.
Hofstatter E, Horvath S, Chagpar A, Wali V, Bossuyt V, Storniolo A, Patwardhan G, Von Wahlde M, Pusztai L. Comparison of epigenetic aging in normal breast tissue from women with and without breast cancer. Journal Of Clinical Oncology 2017, 35: 1522-1522. DOI: 10.1200/jco.2017.35.15_suppl.1522.Peer-Reviewed Original ResearchNormal breast tissueBreast cancerBreast tissueHealthy peersSusan G. Komen Tissue BankIU Simon Cancer CenterNormal breast tissue samplesBreast cancer preventionCohort of womenImportant risk factorKomen Tissue BankLifetime of womenBreast tissue samplesCurrent medicationsTumor characteristicsCancer CenterRisk factorsCancer preventionClinical dataFamily historyReduction mammoplastyHigh riskChronologic ageReproductive historyCancer